Thyreos Inc.
Oak Park, IL
- UEI
- GFGNCMZKKLF7
- CAGE
- 8U0N5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 501 N Elmwood Ave, Oak Park, IL 60302, USA
- Website
- thyreosvaccines.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Bovine respiratory disease (BRD) is the leading cause of illness, death, and economic loss by infectious disease in… | Institute of Food Production and Sustainability | $174,699 | |
| An R2 non-neuroinvasive herpes simplex virus type 2 vaccine - project summary there is an unmet need for a herpes… | National Institute of Allergy and Infectious Diseases | $3,288,038 | |
| Bovine alphaherpesvirus 1 (bohv-1) is endemic in the USA cattle population and responsible for significant economic loss… | Institute of Food Production and Sustainability | $174,235 |
About Thyreos Inc.
Thyreos Inc. is a for-profit corporate entity based in Oak Park, Illinois, registered in SAM.gov since December 2023 with an active registration until May 2026. The company appears to be a biotechnology and vaccine development firm specializing in innovative vaccine platforms, with a particular focus on developing advanced viral vaccines for both animal and human health applications. Its core technological approach centers on the R2 vaccine platform, which creates non-neuroinvasive vaccines that prevent viral pathogens from establishing lifelong infections in nervous systems while maintaining strong immunogenic responses.
Through federal grant awards, Thyreos Inc. has secured multiple project grants from agencies including the U.S. Department of Agriculture's National Institute of Food and Agriculture (NIFA) and the National Institute of Allergy and Infectious Diseases. The company's grant-funded research has concentrated on developing sophisticated vaccines targeting specific viral challenges, including a $174,699 grant to create an integrated vaccine protecting cattle against Bovine Respiratory Disease by expressing protective antigens from multiple viruses, and another grant focused on developing a non-neuroinvasive Herpes Simplex Virus Type 2 vaccine. These projects demonstrate Thyreos' expertise in engineering complex vaccine solutions that address significant health challenges in veterinary and human medical domains, utilizing their proprietary R2 technology platform to create safer, more effective vaccine candidates with improved immunological profiles compared to traditional vaccine designs.
Quick answers
What is Thyreos Inc.'s UEI?
Thyreos Inc.'s Unique Entity ID (UEI) in SAM.gov is GFGNCMZKKLF7.
What is Thyreos Inc.'s CAGE code?
Thyreos Inc.'s CAGE code is 8U0N5.
What is Thyreos Inc.'s primary NAICS code?
Thyreos Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Thyreos Inc. located?
Thyreos Inc.'s physical address in SAM.gov is 501 N Elmwood Ave, Oak Park, IL 60302, USA.
Is Thyreos Inc. registered in SAM.gov?
Yes. Thyreos Inc.'s SAM.gov registration is active through July 29, 2027.
What is Thyreos Inc.'s most recent federal award?
Thyreos Inc.'s most recent federal grant award is Bovine respiratory disease (BRD) is the leading cause of illness, death, and economic loss by infectious disease in… (20253361044937), from Institute of Food Production and Sustainability, on August 15, 2025.
On GovTribe
See Thyreos Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors